Skip to main content

Table 3 Initial data set and validation set results according to axillary nodal macro metastasis involvement

From: Lymph node positivity in different early breast carcinoma phenotypes: a predictive model

  Initial set Validation set
pN0 pN1mi macro   pN0pN1mi macro  
Nb % Nb % p Nb % Nb % p
Nb patients 6400   1981    3178   1013   
Age median (range) 58.4 (18–101) 55 (20–98)   59 (18–100) 56 (25–90)  
<  60 3573 56 128/4 65 < 0.0001 1743 55 631 62 0.0002
 61–65 934 15 232 12   510 16 134 13  
 >  65 1891 30 464 23   922 29 248 24  
Tumor size
  < 10 2872 45 264 13 < 0.0001 1453 46 112 11 < 0.0001
 11 to 20 2665 42 703 36   1310 42 375 37  
  > 20 786 12 998 51   380 12 515 51  
Tumor type
 Ductal 4981 78 1541 78 < 0.0001 2494 79 777 77 < 0.0001
 Lobular 800 13 310 16   382 12 153 15  
 Mixt 82 1 62 3   43 1 39 4  
 Others 531 8 68 3   257 8 43 4  
Grade
 1 2442 39 449 23 < 0.0001 1147 37 208 21 < 0.0001
 2 2841 45 959 49   1453 46 503 50  
 3 1048 17 563 29   540 17 297 29  
LVI
 Negative 4655 86 1006 55 < 0.0001 2287 86 482 53 < 0.0001
 Positive 780 14 815 45   373 14 432 47  
Estrogen receptors
 negative 827 13 319 16 0.0003 414 13 170 17 0.0031
 positive 5570 87 1657 84   2760 87 841 83  
Progesterone receptors
 negative 1751 29 530 28 0.4585 885 29 298 30 0.6346
 positive 4330 71 1371 72   2140 71 681 70  
Hormonal receptors
 negative 732 11 288 15 0.0002 375 12 146 14 0.0306
 positive 5662 89 1687 85   2800 88 864 86  
Tumor sub types
 Luminal A 4780 75 1246 63 < 0.0001 2345 74 627 62 < 0.0001
 Luminal B Her2- 458 7 298 15   272 9 150 15  
 HR+ Her2+ 383 6 138 7   161 5 84 8  
 HR- Her 2+ 178 3 110 6   106 3 56 6  
 Triple Negative 554 9 178 9   269 9 90 9  
Clinical size
 T0 1601 26 230 12 < 0.0001 828 27 105 11 < 0.0001
 T1 3731 61 813 43   1835 61 405 42  
 T2 710 12 673 36   348 11 384 40  
  > T3 30 0 157 8   20 1 76 8